Cyxone announces that exercise of warrants TO3 amounted to 66% – is allocated 62.4 MSEK
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced a positive outcome of the exercise of warrants of series 3 (TO3). A total of 11,622,863 warrants were exercised, corresponding to approximately 66 percent of all warrants, for subscription of 11,622,863 shares at a subscription price of 5.37 SEK per share. By the exercised warrants, Cyxone is thus allocated approximately 62.4 MSEK before issue costs.
Last year, the company carried out a rights issue of units, consisting of a share and a warrant, with the subscription period October 8 to 23, 2018. The exercise period for the warrants of series 3 (TO3) took place during the period September 2 to 18, 2019 and has thus ended. The subscription price for subscription of shares in Cyxone through the utilization of TO3 was set, as previously communicated, at 5.37 SEK per share.
Exercised warrants have been replaced with interim shares (IS) pending registration with the Swedish Companies Registration Office. Conversion of interim shares to shares is expected to take place in about two weeks’ time. Full terms and conditions for TO3 are available on Cyxone's website, www.cyxone.com.
Number of shares and share capital
Through the exercise of the warrants, the number of shares in Cyxone increases by 11,622,864 shares, from 37,457,517 to 49,080,380 shares. The share capital increases by 877,198 SEK, from 2,826,984 SEK, to 3,704,182 SEK.
After the exercise of TO3, the Board of Directors and management have increased their shareholding to 7,010,667 shares, privately and via legal entities, which corresponds to approximately 14.28 percent of the Company.
For existing shareholders who have not exercised any warrants, the dilution amounts to 23.68 percent.
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Phone: +46 (0) 723 816 168
211 22 Malmö, Sweden
This contains such information that Cyxone AB is required to make public under the EU’s Market Abuse Regulation. The information was provided under the auspices of the above contact person for publication on September 25, 2019 at 08.55 CET.
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, firstname.lastname@example.org. www.cyxone.com